A CONSORT analysis of randomised controlled trials for the treatment of invasive aspergillosis

• Published in: Medical mycology (Oxford) 2017-08, Vol.55 (6), p.605-613
• Main Authors: Jones, Brian L, Richardson, Malcolm D, Ingram, Patricia M, Agrawal, Samir G
• Format: Article
• Language: English
• Subjects: Aspergillosis - therapy; Guidelines as Topic; Humans; Invasive Fungal Infections - therapy; Periodicals as Topic - standards; Randomized Controlled Trials as Topic - standards; Research Design - standards; Research Report - standards
• ISSN: 1369-3786; 1460-2709
• DOI: 10.1093/mmy/myw133

Abstract There is no assessment of the reporting quality of antifungal randomized, controlled trials (RCT), upon which guidelines for the treatment of invasive aspergillosis (IA) in patients with hematological malignancy are based. Trial reports were identified through Trip, Cochrane, Medline, and Embase database searches. Report quality was assessed using the 25-item CONSORT checklist and a rating scale of 1 (strongly disagree) to 4 (strongly agree). The primary endpoint was quality as assessed by mean group-scores among papers published at the time of the most recent IA treatment guidelines. Seven RCTs were identified for analysis. Overall mean group-score for all seven papers was 2.44 (out of a total of four). There were significant differences between publications regarding overall reporting quality (P < .001) and specifically for the Methods and Results (P = .004 and P = .010, respectively), which best reflect data quality. The Cornely trial report achieved the highest mean group-score overall (3.15 ± 0.93; 95% CI, 2.82, 3.47), as well as for Methods (3.36) and Results (3.40). Mean group scores also showed that it was of significantly higher overall quality than the other six publications (P-value range; .012 to